The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Therapeutic potential of CPI-482 for AML and post-MPN AML
Raajit Rampal, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses a study investigating the therapeutic potential of the lysine-specific demethylase 1 (LSD1) inhibitor CPI-482 for treating acute myeloid leukemia (AML) and post-myeloproliferative neoplasm (MPN) AML. CPI-482 administration resulted in significant tumor growth inhibition in SET-2 and HEL 92.1.7 JAK2 mutant AML xenograft mouse models. To further confirm these findings, the research group used a murine model of combined Tp53 loss and Jak2 mutations. Mice were randomized to treatment with vehicle, ruxolitinib, or CPI-482. Results show that treatment with CPI-482 significantly prolonged the survival of mice versus either ruxolitinib or vehicle. Additionally, there was a significant decrease in the spleen size of animals treated with CPI-482 compared to ruxolitinib or vehicle. Finally, it was possible to observe restoration of normal hematopoiesis in the mice treated with CPI-482. This data supports the potential therapeutic impact of the LSD1 inhibitor CPI-482 in AML in the context of the JAK2V617F mutation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
